Kymera Therapeutics, Inc.KYMREarnings & Financial Report
Nasdaq
NextFeb 27, 2026
KYMR Q3 2025 Key Financial Metrics
Revenue
$2.8M
Gross Profit
$0
Operating Profit
$-92.5M
Net Profit
$-82.2M
Gross Margin
N/A
Operating Margin
-3347.4%
Net Margin
-2973.0%
YoY Growth
-26.1%
EPS
$-0.94
Financial Flow
Kymera Therapeutics, Inc. Q3 2025 Financial Summary
Kymera Therapeutics, Inc. reported revenue of $2.8M for Q3 2025, with a net profit of $-82.2M (-2973.0% margin). Cost of goods sold was $2.8M, operating expenses totaled $92.5M.
Key Financial Metrics
| Total Revenue | $2.8M |
|---|---|
| Net Profit | $-82.2M |
| Gross Margin | N/A |
| Operating Margin | -3347.4% |
| Report Period | Q3 2025 |
Kymera Therapeutics, Inc. Annual Revenue by Year
Kymera Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $47.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $47.1M |
| 2023 | $78.6M |
| 2022 | $46.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.9M | $10.3M | $25.6M | $3.7M | $7.4M | $22.1M | $11.5M | $2.8M |
| YoY Growth | 196.7% | 8.7% | 55.3% | -20.9% | -84.6% | 114.8% | -55.3% | -26.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $575.8M | $868.3M | $826.0M | $1.03B | $978.0M | $918.3M | $1.13B | $1.10B |
| Liabilities | $180.8M | $157.0M | $141.1M | $141.9M | $142.4M | $132.1M | $159.6M | $155.8M |
| Equity | $395.0M | $711.2M | $684.9M | $892.9M | $835.6M | $786.2M | $971.5M | $946.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $8.0M | $-39.6M | $-42.9M | $-50.2M | $-61.8M | $-79.2M | $-59.9M | $-27.1M |